|Videos|March 13, 2023
Inotuzumab as an Option for Patients with R/R Acute Lymphoblastic Leukemia
Dr Jabbour and fellow panelists share their thoughts on the benefits of Inotuzumab ozogamicin, particularly in a pre-allogeneic HSCT setting.
Advertisement
Episodes in this series
Advertisement
Related to this article
Fadi Haddad, MD, discusses TKI adherence barriers, adverse effect management, and the role of alternative TKI formulations in CML.
Updated ARC-20 data showed casdatifan activity as monotherapy and in combinations across treatment lines in advanced clear cell RCC.
The designation covers QTX3034 plus cetuximab with or without FOLFOX; phase 1 data showed a 25% confirmed ORR with the doublet in CRC and PDAC.
MimiVax and Roswell Park announced phase 2b SURVIVE trial results evaluating the SurVaxM vaccine in newly diagnosed glioblastoma.
Faculty at an OncLive Scientific Interchange and Workshop discussed individualizing frontline immune checkpoint inhibitor selection in metastatic NSCLC.
The FDA granted fast track designation to MC001 for pancreatic cancer.
The NCCN update adds locally advanced CSCC to the category 2A listing cosibelimab received in metastatic disease in 2025.
In TASKIN, the 12-month OS rate was 61.3% with vilamakitug vs 55.7% with placebo plus trifluridine/tipiracil.
Advertisement
Advertisement
Trending on OncLive
1
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
3
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
4
Dr Warren on the Goal of the 4WARD Trial Evaluating Mavorixafor in Chronic Neutropenia
5